DVP II Life sciences & health 4-14 May 2014
description
Transcript of DVP II Life sciences & health 4-14 May 2014
![Page 1: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/1.jpg)
DVP IILife sciences &
health4-14 May 2014
![Page 2: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/2.jpg)
2DVP Health & life sciencesObjectives:
Participants: 8 experts in
healthcare & life sciences from different courtiers
Experience the Netherlands first hand
Gain insight into the country’s history, culture and people
Obtain relevant knowledge and worthwhile contacts to satisfy personal and professional needs and interests
Pursue mutually beneficial opportunities, leads, contacts, projects, etc., with Dutch individuals and organisations
![Page 3: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/3.jpg)
3
![Page 4: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/4.jpg)
4
Life Sciences in the Netherlands
![Page 5: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/5.jpg)
5
Life Sciences in the Netherlands
![Page 6: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/6.jpg)
6
8 University Medical Centers, 14 Research Universities (incl. 3 Technical Universities), 137 general hospitals
Biobanks and patient cohorts for research purposes
Life Sciences in the Netherlands
![Page 7: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/7.jpg)
7
![Page 8: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/8.jpg)
8
• Dedicated Bio Science Park (since 1984) with a clear focus• Specialisation in biomedical and bio molecular life sciences;
biopharmaceutical production• 90 life science companies with ± 3,800 employees • ~16,000 employees in total working at 1 location• LUMC with ± 6,800 employees in total • another 6 academic/education centers with ± 2,600 employees in life science related jobs • the largest number of life sciences start-ups• 2 musea: Naturalis Biodiversity Center and Corpus Experience• 2 skilled labour pools
![Page 9: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/9.jpg)
Facilities• Expat centre
• Naturalis Biodiversity Center
• Netherlands Centre for Electron Nanoscopy
• Biotech Training Facility• Realistic biopharmaceutical plant, for training, education and demonstration
• Bridge gap between schooling and practice
• Location close to education institutes and industry
• Construction starts summer 2014, opening autumn 2015
• Investment ~ € 10 M
![Page 10: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/10.jpg)
Service companies Proxy Laboratories: QA, QC, stability testing, assay development, validation Microsafe Laboratories: microbiology testing Galapagos: target discovery Xendo: process development, drug development, validation, RA, GMP, pharmaceutical engineering, clinical trials, bio analytical service Batavia Bioservices: early process development OctoPlus/Dr. Reddy’s: drug delivery technology TLC: drug delivery technology TNO Quality of life: drug development BaseClear: DNA sequencing, forensic support CHDR: clinical trials BioTop Medical: regulatory Affairs ServiceXS: genomics service center LifeScienceGo!: business resources Chiltern: full clinical research services from early phase to late phase Halix: CMO
![Page 11: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/11.jpg)
11
Center for Human Drug Research www.chdr.nl
![Page 12: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/12.jpg)
12
Center for Human Drug Research
![Page 13: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/13.jpg)
13
• Mission of both centres is to maximise effective utilisation of new IP (social, economic and financial drivers are relevant)
• Evaluate & protect new inventions• Identify and negotiate licensees• Assist in new company formation (mentoring, pre-seed &
seed funds)• Advise university on EU and other major research funding
opportunities • Negotiate research contracts, particularly complex
public/private partnerships
Leiden Technology Transfer OfficeLeiden University and Leiden University Medical Centre
http://www.research.leiden.edu/luris/industry/
![Page 14: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/14.jpg)
14
![Page 15: DVP II Life sciences & health 4-14 May 2014](https://reader034.fdocuments.in/reader034/viewer/2022051317/568168f3550346895ddffc3e/html5/thumbnails/15.jpg)
15
Institute for Health Policy and Management, Erasmus University